Belpointe Asset Management’s Coherus Oncology CHRS Stock Holding History

Belpointe Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-401	Closed	-$2.74K	–	1050
2023 Q1	$2.74K	Sell	401 -1,590	-80%	-$12.3K	﹤0.01%	3221
2022 Q4	$15.8K	Buy	+1,991	New	+$15.3K	﹤0.01%	2351

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Belpointe Asset Management's CHRS Position: Q2 2023 in Review

Belpointe Asset Management sold out of Coherus Oncology (CHRS) in Q2 2023, closing a stake of 401 shares — an estimated $2.74K sold.

Belpointe Asset Management first reported a position in CHRS in Q4 2022 and held it in 2 quarters. The position peaked at $15.8K in Q4 2022. 161 funds tracked by Wall St. Rank hold CHRS as of Q2 2023.

Belpointe Asset Management reported no remaining Coherus Oncology position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 401 Coherus Oncology shares in Q2 2023, an estimated $2.74K.
Belpointe Asset Management first reported a position in Coherus Oncology in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's Coherus Oncology position peaked at $15.8K in Q4 2022.
161 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.